Plasma NT-pro brain natriuretic peptide guided therapy ofβ1-blocker to patients with moderate and severe heart failure
10.3969/j.issn.1671-8348.2015.24.015
- VernacularTitle:NT-proBNP 指导中重度心力衰竭患者β1受体阻滞剂使用的临床研究
- Author:
Kun YANG
;
Bo PAN
;
Jinglan DAI
;
Haigang MOU
;
Wei LIANG
;
Shouyan YANG
- Publication Type:Journal Article
- Keywords:
NT-proBNP;
heart failure;
β1-blocker;
peptides;
natriuretic petide,brain
- From:
Chongqing Medicine
2015;(24):3355-3356,3359
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the feasibility of plasma NT-pro brain natriuretic peptide guided therapy of β1-blocker to patients with moderate and severe heart failure.Methods A total of 1 95 patients with moderate and severe heart failure were ran-domized to the clinical group and the BNP group.The use of β1-blocker was guided by monitoring clinical representation and the changes of BNP values respectively.The duration of initiative use ofβ1-blocker,the recurrence of heart failure,the mortality due to heart failure and the mean dosage ofβ1-blocker were observed and analysed.Results Compared with the clinical group,the time of initiative use ofβ1-blocker was significantly shorter in NT-proBNP group[(5.89±1.76)d vs .(7.03±2.08)d,P <0.01].The mean dosage ofβ1-blocker is significantly higher in BNP group than that in clinical group[(47.65 ± 13.09 )mg/d vs .(35.08 ± 1 1.08) mg/d,P <0.01].The recurrence and mortality of heart failure were similar in two groups(P >0.05).Conclusion NT-proBNP-guided therapy ofβ1-blocker might contribute to early use and tolerance of higher dosage ofβ1-blocker in patients with NYHA Ⅲ-Ⅳ class heart function,with no extra adverse event.
